InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,631.22
(
0.28%
)
US TECH 100
19,894.80
(
0.52%
)
Dow Jones
40,211.72
(
0.53%
)
Brent Oil
84.34
(
-0.30%
)
Bitcoin
64,383.28
(
5.93%
)
Post# of 30387
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Gold Seeker

Send PM Follow Ignore
Followers 29
Posts 9421
Boards Moderated 0
Alias Born 04/30/2006

Gold Seeker

Re: enos post# 8224

Monday, 03/12/2007 11:02:31 AM

Monday, March 12, 2007 11:02:31 AM

Post# of 30387
This cancer marker would be a genetic test so it will remain with Abbott at their molecular division. It is also another semi exclusive agreement as with BioCurex. Another marker that I previously posted about was PCA3. It is also a genetic marker. Both of the tests would be expensive, probably in the range of several hundred dollars. The PCA3 test requires manually massaging the prostate during the urine collection process and that would be done with the INDEX finger. The good part, I guess, would be running both tests with the same sample collection.

http://www.prostate-cancer.org/education/preclin/Torres_PCA3.html
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up